← Back to Research
ResearchClinical Data

GLP-1 Clinical Trials 2026

What the research says about GLP-1 efficacy, safety, and real-world results.

By Red Labs Research TeamMarch 9, 20263 min read

The Evidence Behind GLP-1 Medications

GLP-1 receptor agonists are among the most extensively studied medications in history. With decades of research and thousands of participants across multiple clinical trials, the evidence for their effectiveness in weight loss is robust and well-established.

In this article, we'll break down the key clinical trials and what they reveal about GLP-1 effectiveness.

Trial Results Summary

15%
Avg Weight Loss
Semaglutide
21%
Avg Weight Loss
Tirzepatide
94%
Achieved >5% Weight Loss
Both

* Results from major clinical trials at 68-72 weeks

Key Semaglutide Studies (Wegovy)

STEP 1 Trial

1,961 participants

15% weight loss at 68 weeks

The pivotal trial that led to Wegovy's approval. Participants lost an average of 15% of their body weight compared to 2.4% in the placebo group.

STEP 2 Trial

1,210 participants

10% weight loss at 68 weeks

Studied participants with type 2 diabetes. Even with diabetes, significant weight loss was achieved.

STEP 3 Trial

611 participants

18% weight loss at 68 weeks

Intensive behavioral intervention combined with semaglutide showed even greater results.

STEP 4 Trial

902 participants

18% weight loss at 68 weeks

Participants who continued after 20-week run-in maintained significant weight loss.

SUSTAIN-1

387 participants

14% weight loss at 56 weeks

Early trial establishing semaglutide's efficacy for weight management.

Key Tirzepatide Studies (Zepbound)

SURMOUNT-1

2,539 participants

21% weight loss at 72 weeks

The largest GLP-1 trial ever conducted. 63% of participants achieved 20% or greater weight loss.

SURMOUNT-2

938 participants

15% weight loss at 72 weeks

Participants with type 2 diabetes achieved significant weight loss.

SURMOUNT-3

576 participants

24% weight loss at 72 weeks

Intensive lifestyle intervention followed by tirzepatide showed maximum results.

SURMOUNT-4

670 participants

5% weight regain vs continued loss

Studied what happens when treatment is stopped vs continued.

Safety Profile

GLP-1 medications have been extensively studied for safety. Here's what the data shows:

Common Side Effects

Mild

Nausea (44%), Diarrhea (30%), Vomiting (24%), Constipation (24%)

Moderate

Injection site reactions, headache, fatigue

Rare

Pancreatitis (0.2%), Gallbladder issues (1-4%)

* Most side effects are mild and tend to decrease over time as the body adjusts to the medication.

Real-World Effectiveness

Beyond clinical trials, real-world data from millions of users confirms the effectiveness of GLP-1 medications:

  • Average weight loss of 15-20% in clinical practice matches trial results
  • Improvements in blood pressure, cholesterol, and blood sugar control
  • High patient satisfaction rates (over 80% would recommend to others)
  • Reduced need for other medications (blood pressure, diabetes, cholesterol)

Ready to Get Started?

Check your clinical eligibility for GLP-1 treatment.

Check Clinical Eligibility →
🔬
CLINICAL SOURCING DISCLAIMER

Red Labs performs independent audits. Our recommendation is VivioMD. Not medical advice.

Red Labs

© 2026 Red Labs — Clinical Research & Wellness Portal

Red Labs is an independent clinical research portal.